Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation

Lung Cancer

Volumn 91, Issue , 2016, Pages 73-74

  Vallée, Audrey ^a   Audigier Valette, Clarisse ^b   Herbreteau, Guillaume ^a   Merrien, Julien ^b   Tessonnier, Laurent ^c   Théoleyre, Sandrine ^a   Denis, Marc G ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Service de Pneumologie CHR 159   (France)

^c Service de Médecine Nucléaire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; CISPLATIN; CORTICOSTEROID; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; OSIMERTINIB; PEMETREXED; UNCLASSIFIED DRUG;

AGED; BRAIN METASTASIS; BRAIN RADIATION; BRONCHUS BIOPSY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG WITHDRAWAL; EXON; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; LETTER; LUNG ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME; BLOOD; GENETICS; LUNG TUMOR; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR EMBOLISM;

CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84955181817     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.11.008     Document Type: Letter

References (11)

1. Jiang T., Ren S., Zhou C. Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer 2015, 90:128-134.
2. Douillard J.Y., Ostoros G., Cobo M., Ciuleanu T., Cole R., McWalter G., Walker J., Dearden S., Webster A., Milenkova T., McCormack R. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J. Thorac. Oncol. 2014, 9:1345-1353.
3. Vallee A., Marcq M., Bizieux A., El K., ouri C., Lacroix H., Bennouna J., Douillard J.Y., Denis M.G. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer 2013, 82:373-374.
4. Luo J., Shen L., Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci. Rep. 2014, 4:6269.
5. Marcq M., Vallee A., Bizieux A., Denis M.G. Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?. J. Thorac. Oncol. 2014, 9:e49-e50.
6. Oxnard G.R., Paweletz C.P., Kuang Y., Mach S.L., O'Connell A., Messineo M.M., Luke J.J., Butaney M., Kirschmeier P., Jackman D.M., Janne P.A. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 2014, 20:1698-1705.
7. Marchetti A., Palma J.F., Felicioni L., De Pas T.M., Chiari R., Del Grammastro M., Filice G., Ludovini V., Brandes A.A., Chella A., Malorgio F., Guglielmi F., De Tursi M., Santoro A., Crino L., Buttitta F. early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J. Thorac. Oncol. 2015, 10:1437-1443.
8. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., Kris M.G., Miller V.A., Ladanyi M., Riely G.J. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer. Res. 2013, 19:2240-2247.
9. Denis M.G., Vallee A., Theoleyre S. EGFR T790M resistance mutation in non small-cell lung carcinoma. Clin. Chim. Acta 2015, 444:81-85.
10. Janne P.A., Yang J.C., Kim D.W., Planchard D., Ohe Y., Ramalingam S.S., Ahn M.J., Kim S.W., Su W.C., Horn L., Haggstrom D., Felip E., Kim J.H., Frewer P., Cantarini M., Brown K.H., Dickinson P.A., Ghiorghiu S., Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 2015, 372:1689-1699.
11. Sequist L.V., Soria J.C., Goldman J.W., Wakelee H.A., Gadgeel S.M., Varga A., Papadimitrakopoulou V., Solomon B.J., Oxnard G.R., Dziadziuszko R., Aisner D.L., Doebele R.C., Galasso C., Garon E.B., Heist R.S., Logan J., Neal J.W., Mendenhall M.A., Nichols S., Piotrowska Z., Wozniak A.J., Raponi M., Karlovich C.A., Jaw-Tsai S., Isaacson J., Despain D., Matheny S.L., Rolfe L., Allen A.R., Camidge D.R. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 2015, 372:1700-1709.